The Injective price has reached a crucial technical level following a descending triangle breakout, currently testing the 200-day EMA around $5. Market analysts note that clearing the $5 mark could open potential targets at $5.50 and $6, while a failure to hold this level could risk further downside.
RWA Infrastructure and Institutional Pilots
The technical test coincides with a major expansion of Injective's tokenization infrastructure. POSCO International and LG CNS recently launched a pilot utilizing live trade data and real commercial receivables on the network. During the pilot, artificial intelligence agents reviewed Letters of Credit and supporting documents, while receivables were issued as permissioned onchain assets equipped with embedded compliance controls.
This development adds to Injective's broader push into institutional finance. The network reports that it has previously tokenized institutional funds, public equities, trade receivables, and pre-IPO shares involving companies such as SpaceX and OpenAI.
Regulatory Milestones and Market Position
In addition to its technical developments, Injective announced it is now an SEC-registered transfer agent. This designation makes it the first layer-1 blockchain to combine native real-world asset (RWA) infrastructure with regulated recordkeeping capabilities intended for American capital markets.
By integrating RWA infrastructure, AI-powered financial tools, and regulated rails within a single network, Injective is positioning itself as infrastructure for compliant capital markets. Despite these fundamental developments, market participants continue to watch the charts closely to see if INJ can sustain a breakout above the key $5 threshold.
